Vertex Announces CASGEVY® Reimbursement for SCD in England
– Agreement means eligible sickle cell disease (SCD) patients in England now have access to CASGEVY – – Agreement for CASGEVY in transfusion-dependent beta thalassemia...
Category : Healthcare and Pharmaceutical
GE HealthCare Invests $138M in Cork Facility for Contrast Media
GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A...
Meiji Seika Pharma Gets Approval for Domestic KOSTAIVE® Production
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment...
Ferrer recognized for best-in-class ethics and compliance program
Ferrer has achieved Compliance Leader Verification™, the prestigious recognition granted by Ethisphere, which distinguishes the pharmaceutical company as a global leader in upholding ethical and...
Osta Therapeutics adds two experts to tackle antibiotic resistance
Osta Therapeutics, a biotechnology company developing smart drugs to fight antibiotic resistance, today announced the appointments of Dr. Gilles Courtemanche as Senior Scientific Advisor and...
Nomi Health named ACAP preferred vendor to boost health equity
Nomi Health Joins the Association for Community Affiliated Plans to Support Not-for-Profit Safety Net Health Plans Nomi Health, a leading direct healthcare company, today announced...
Owkin doses first patient in AI-optimized trial of OKN4395.
Owkin, the first end-to-end AI-biotech that uses agentic AI to revolutionize drug discovery, development, and diagnostics, today announced that the first patient has been dosed...
Kyowa Kirin, Swixx expand POTELIGEO® access in CEE
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd., and Swixx BioPharma AG today announced that the Croatian National Health Insurance...
Merck, Eisai Update Phase 3 LEAP-015 Trial for GE Adenocarcinoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-015 trial evaluating...
Innate Pharma Doses First Patient in Phase 1 Study of IPH4502
IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4 Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)...